Two Different Tools, One Easy Confusion

CRISPR and RNA interference both sound like genetic medicine, and both are. But they do opposite things. CRISPR edits the DNA itself, permanently changing the genome. RNA interference silences a gene by destroying its messenger RNA, leaving the DNA untouched. Porter Stansberry’s Ignition Point pitch is a silencing story, which means investors who lump CRISPR names into it are reaching for the wrong drawer.

The confusion is common because both technologies are frequently described with the same shorthand. The clean way to keep them straight is to remember the verb. Editing means the gene itself changes. Silencing means the gene stays put and its instructions get blocked. We break down the silencing half from first principles in our gene silencing explainer.

CRISPR Edits the DNA

CRISPR uses a system called CRISPR-Cas9, borrowed from bacteria, to cut DNA at a precise location. Once the DNA is cut, the cell’s repair machinery can be steered to disable a gene or to insert a corrected sequence. The change is permanent and inherited by the cell’s descendants. That makes CRISPR a one-time intervention, which is its biggest promise and its biggest risk, since a permanent edit cannot be easily undone.

The leading pure-play CRISPR names are CRISPR Therapeutics (CRSP) and Intellia (NTLA). Both are gene-editing companies, and both are trying to turn a powerful laboratory tool into durable medicines. Their programs tend to target diseases where a permanent fix is the goal, which is a different bet than the repeat-dose silencing drugs in the Ignition Point sleeve.

RNAi Silences the Messenger

RNA interference, by contrast, does not touch DNA. It introduces a short RNA strand that guides a protein complex to destroy the messenger RNA produced by a target gene. The protein never gets made, but the gene is untouched and the effect fades as the drug is cleared. That temporary, dose-dependent quality is why we call it silencing rather than editing. We cover the drug class in detail in our RNA interference explainer.

For a condition like high lipoprotein(a), where the problem is that a gene produces too much of a protein for a lifetime, silencing is the natural fit. There is nothing to permanently edit. There is a faucet to turn down, repeatedly, for as long as the patient lives with the condition.

Why the Distinction Drives Valuations

Editing and silencing companies get valued differently because their risk and economics differ. A one-time edit is a cure-sized bet with an irreversible safety read and a one-time payment. A repeat-dose silencing drug is a chronic treatment with years of recurring revenue but the burden of proving long-term safety and real outcomes. Confusing the two means applying the wrong risk model to a stock.

Why CRISPR Is Not the Play Here

For a target like lipoprotein(a), gene editing would be the wrong tool even if it worked perfectly. The gene that drives Lp(a) production is not broken. It is doing what it is supposed to do, just at a level that raises cardiovascular risk. Permanently editing that gene in an adult is a drastic answer to a problem that can be managed by turning the gene down on an ongoing basis.

CRISPR also carries its own unresolved challenges. Delivery into the right tissues is hard, off-target edits are a permanent concern, and the economics of a one-time edit are unforgiving. None of that means editing is a dead end; it means editing solves a different class of problem than the one the Ignition Point thesis targets. The pitch is a silencing story because silencing fits. Investors who keep the two buckets separate will read the promo correctly, while those who treat every gene-based company as interchangeable will keep mispricing both.

The timelines also differ. Editing programs move slowly because a permanent change demands more safety data before regulators will sign off. Silencing programs, built on repeat dosing of a temporary effect, can advance through trials with a shorter safety runway. That is one reason the silencing names in the Ignition Point pitch are closer to commercialization than most editing programs, and it is another way the two categories drift apart in practice.

For a reader working through the Ignition Point pitch, the test is simple. If a name is described in terms of cutting DNA or permanently correcting a gene, it is an editing story and not part of this thesis. If it is described in terms of lowering a protein’s production, it belongs in the silencing bucket the promo is actually about.

The Bottom Line

CRISPR Therapeutics and Intellia are gene-editing companies, not gene-silencing companies, and the Ignition Point pitch is not about them. CRISPR edits DNA permanently. RNA interference silences it temporarily. If you can hold that single distinction, you can sort nearly every biotech name in the theme into the right bucket before you ever read a price target.

Ready to see the research? Click here to access Porter Stansberry’s report.

NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.